Review of adolescent substance use and responses in the WHO Western Pacific Region
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
This project will conduct the first-ever outpatient RCT to test the efficacy, safety and cost-effectiveness of the pharmaceutical cannabinoid nabiximols (Sativex®) for treating cannabis dependence.
This innovative, integrated care project was implemented in the South Eastern Sydney Local Health District to improve integration of services provided to those who are frequent attenders to the Emergency Department and have drug and alcohol use disorders.
This project undertakes research to understand the pathways of vulnerable adolescents and the role of the Ted Noffs Program for Adolescent Life Management (PALM) in assisting young people to get their lives back on track.
The rapidity of overdose and death is of major clinical importance. Essentially, is there time to intervene, or are such deaths typically so rapid as to preclude meaningful intervention? The presence of 6-monoacetly-morphine (6MAM) is indicative of a rapid death following heroin administration.
Compulsive hoarding is a debilitating disorder. Little is known of the substance use of hoarders, or the circumstances in which they die.
In this study, we will undertake detailed analyses of the largest cross-national epidemiologic study of mental and substance use disorders ever conducted. The WHO World Mental Health Survey (WMHS) initiative is a massive, unique endeavour.
This study examines the utilisation of opioid substitution therapy among a large community sample of chronic non-cancer pain patients receiving long-term opioid substitution therapy (OST).
Globally, harmful alcohol use continues to be a major modifiable contributor to the burden of disease.
This research project seeks to examine the patterns and costs of Pharmaceutical Benefits Scheme-subsidised opioid use, including extra-medical use, in the Australian population.